French molecular imaging firm Advanced Accelerator Applications (AAA) has signed an agreement with Italian manufacturing firm Itel to manufacture and market radiopharmaceuticals in southern Italy.
The agreement is contingent upon Itel completing all qualification procedures and receiving authorization by the Italian Medicines Agency.
Itel plans to manufacture fluorine-18 (F-18) radiopharmaceuticals under the AAA license in its production plant in Ruvo di Puglia, Italy, and distribute them to PET centers in select regions of southern Italy through its ItelPharma business unit.
AAA's key F-18 product is Gluscan, a branded FDG-PET imaging agent designed for the diagnosis of certain diseases, primarily in oncology, by assessing glucose metabolism.
